eSense-Lab Limited announced that it signed a Letter of Intent (LOI) with SeaLaria Ltd. (SeaLaria). The LOI is for a joint venture in developing new products based on the synergistic effect of eSense's terpene strains, and SeaLaria's unique gelatinised red algae. The initial focus of the joint venture will be on healthcare and consumer anti-viral hand sanitisers. The infusion of terpenes to enhance the anti-viral potency and reduce the existing high alcohol content present in hand sanitisers and related products will be tested and produced. eSense's CTO, Dr. Eyal Kalo, said the lab teams have been engaged to formulate the first experimental batch of a gel-based, alcohol free sanitiser. Preliminary results have been received and are currently being considered by the Company. Additionally, eSense is developing an ointment to infuse combinations of SeaLaria's gelatinised algae along with eSense's best anti-inflammatory and anti-proliferative terpene blends. eSense plans to enter collaboration with hospital-based dermatology key opinion leaders to examine the therapeutic effects of these terpene/algae combinations on skin disorders. Under the new leadership team eSense has been exploring a new commercialisation structure through joint venture agreements across multiple revenue-generating markets. In particular, the Company is researching innovative, evidence-based applications of terpenes for the medical, wellness, cosmetic, and nutritional markets. Like the SeaLaria LOI, eSense intends to provide its proprietary terpenes technology to infuse the flavour and fragrance qualities and medicinal and well-being benefits into a range of products. The structure will leverage its partners' experience in marketing, sales and distribution in their specific markets.